PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

The PROTECT study

Low and comparable rates of stent thrombosis found with zotarolimus- and sirolimus-eluting stents: The PROTECT study

2012-08-27
(Press-News.org) Munich, Germany – Rates of stent thrombosis at three years were low and comparable between zotarolimus-eluting and sirolimus-eluting stents, according to findings from the PROTECT study described here today at ESC Congress 2012.

Presenting the results, Professor William Wijns from the Cardiovascular Center in Aalst, Belgium, said that the decline in rates of stent thrombosis seen recently and in the PROTECT (Patient Related OuTcomes with Endeavor versus Cypher Stenting) study was probably explained by several factors, including "improvements in patient selection, procedural techniques, and duration of and compliance with dual antiplatelet therapy". Concerns about the safety of drug-eluting stents (DES) had emerged at ESC Congress 2006 when retrospective studies proposed that DES were subject to a higher risk of stent thrombosis (with a trend towards more late stent thrombosis) than bare-metal stents.

The effect of DES on vessel healing, long-term safety, particularly stent thrombosis, and clinical outcomes has been shown to vary according to drug, polymer and characteristics of the stent. The PROTECT study was thus designed to determine prospectively the safety profile of two DES with different antiproliferative properties.

This, said Professor Wijns, was the largest comparative DES study performed as an open-label, randomised trial. It compared the effect zotarolimus-eluting (E-ZES) and sirolimus-eluting (C-SES) stents in a broad group of patients and lesions, including those with stable and acute coronary syndrome and single or multivessel disease, and with a mix of simple and/or complex lesions. The primary outcome of the study was definite or probable stent thrombosis at three years, with a main secondary outcome of mortality and large non-fatal MI.

PROTECT ultimately randomised 8709 patients equally into each study arm and, for the primary endpoint, followed them up to three years. At this point, the rates of definite or probable stent thrombosis did not differ between groups (1.4% for E-ZES and 1.8% for C-SES; HR 0.81, 95% CI 0.58-1.14, p=0•22).

Rates of death and large non-fatal MI were also similar (5.3% vs 6.0%; HR 0.88, 95% CI 0.73-1.05, p=0.16). Dual antiplatelet therapy (DAPT) was used in 96.5% patients at discharge, 87.8% at one year, 36.6% at two years, and 30.0% at three years.

The investigators found a low incidence of definite stent thrombosis in the C-SES arm at one year when DAPT use was over 85%, but a more than three-fold increase in the rate per year when DAPT use decreased to less than 40%. In the E-ZES arm the incidence of definite very late stent thrombosis decreased two-fold after one year, despite decreasing DAPT regimen. This trend, said Professor Wijns, was consistent with the hypothesis that DAPT use may have a different long-term clinical relevance according to the type of stent used.

Follow-up to five years, currently in progress, will determine whether the rates of 'definite' as well as 'definite or probable' stent thrombosis diverge further and translate into differences in clinical safety.

### Notes to editors

Please note that picture and CV from the author, abstract, picture and CV from spokesperson can be found here The PROTECT study was sponsored by Medtronic.

About the European Society of Cardiology www.escardio.org The European Society of Cardiology (ESC) represents more than 75,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

About ESC Congress 2012 The ESC Congress is currently the world's premier conference on the science, management and prevention of cardiovascular disease. ESC Congress 2012 takes place 25-29 August at the Messe München in Munich. The scientific programme is available at: http://spo.escardio.org/Welcome.aspx?eevtid=54 More information is available from the ESC Press Office at press@escardio.org. END


ELSE PRESS RELEASES FROM THIS DATE:

The FAST-MI program study

2012-08-27
Munich, Germany – Data from four French nationwide registries of STEMI (ST-elevation myocardial infarction) patients initiated five years apart and covering more than 15 years show that mortality rate decreased by 68% over this period, from 13.7% to 4.4%. Around one quarter of this mortality reduction could be attributed to a change in patient characteristics. Even after adjusting for the use of primary percutaneous coronary intervention (PCI) and reperfusion therapy, there still remained a substantial decrease in early mortality rate (>60%), underlining the importance ...

The ASTRID study

2012-08-27
Munich, Germany – The German Aortic Valve Registry (GARY) was started in July 2010 and is the only registry so far to include both transcatheter aortic valve implantation (TAVI) and conventional aortic valve replacements and repair.(1) The intention is to deliver a complete picture of current and future practice of treating aortic valve disease and to deliver reliable data on the short and long-term outcome of different treatment strategies. This specifically includes data about quality of life before and after treatment besides numerous medical variables. Participation ...

The ACCESS-EU study

2012-08-27
Munich, Germany –The percutaneous catheter-based treatment of mitral regurgitation with the MitraClip system improves symptoms and cardiac function at one-year, according to results of a prospective observational study presented here today at ESC Congress 2012. ACCESS-EUROPE (ACCESS-EU) was a multicentre study of the MitraClip system in a commercial setting in 567 patients enrolled at 14 European sites, the largest group of patients evaluated to date. The results were presented by the study's co-principal investigator Professor Wolfgang Schillinger of the Universitätsmedizin ...

The ORIGIN-GRACE study

2012-08-27
Munich, Germany – A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites. However, while insulin glargine did significantly reduce the secondary outcomes of the study ...

pH-sensitive liposomal cisplatin improves peritoneal carcinomatosis treatment without side-effects

2012-08-27
Scientists at the Oswaldo Cruz Foundation and Federal University of Minas Gerais, led by Dr. Andréa Teixeira-Carvalho and Dr. Mônica Cristina de Oliveira, have developed and characterized a circulating and pH-sensitive liposome containing cisplatin (SpHL-CDDP) aiming to promote the release of cisplatin near the tumor as well as decreasing toxicity. The development of analog drugs and new formulations are current strategies for increasing the effectiveness and safety of cisplatin as an anti-peritoneal carcinomatosis drug. The results, which appear in the August 2012 issue ...

Lack of sleep found to be a new risk factor for aggressive breast cancers

2012-08-27
Lack of sleep is linked to more aggressive breast cancers, according to new findings published in the August issue of Breast Cancer Research and Treatment by physician-scientists from University Hospitals Case Medical Center's Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University. Led by Cheryl Thompson, PhD, the study is the first-of-its-kind to show an association between insufficient sleep and biologically more aggressive tumors as well as likelihood of cancer recurrence. The research team analyzed medical records and survey ...

People of normal weight with belly fat at highest death risk, Mayo Clinic study

2012-08-27
ROCHESTER, Minn. -- People who are of normal weight but have fat concentrated in their bellies have a higher death risk than those who are obese, according to Mayo Clinic research presented today at the European Society of Cardiology Congress in Munich. Those studied who had a normal body mass index but central obesity -- a high waist-to-hip ratio -- had the highest cardiovascular death risk and the highest death risk from all causes, the analysis found. "We knew from previous research that central obesity is bad, but what is new in this research is that the distribution ...

Healthy lifestyle reduces the risk of hypertension by two thirds

2012-08-27
Munich, Germany – Healthy behaviours regarding alcohol, physical activity, vegetable intake and body weight reduce the risk of hypertension by two thirds, according to research presented at the ESC Congress today. The findings were presented by Professor Pekka Jousilahti from National Institute for Health and Welfare. According to the World Health Organization, hypertension is the leading cause of mortality in the world, contributing annually to over 7 million deaths (about 15% of all deaths). Therefore, prevention of hypertension is essential to improving health and ...

Team of researchers finds a link between cold European winters and solar activity

2012-08-27
Scientists have long suspected that the Sun's 11-year cycle influences climate of certain regions on Earth. Yet records of average, seasonal temperatures do not date back far enough to confirm any patterns. Now, armed with a unique proxy, an international team of researchers show that unusually cold winters in Central Europe are related to low solar activity - when sunspot numbers are minimal. The freezing of Germany's largest river, the Rhine, is the key. Although the Earth's surface overall continues to warm, the new analysis has revealed a correlation between periods ...

Energy drinks improve heart function

2012-08-27
Munich, Germany – Consuming energy drinks can exert acute positive benefits on myocardial performance, according to research presented today at the ESC Congress by Dr Matteo Cameli from University of Siena. "In recent years the energy drink market has exploded, with more people than ever before turning to these products as quick 'pick me ups', whether to stay awake during all night study vigils or gain the edge in sport," said Dr Cameli. "With energy drinks containing both caffeine and taurine concerns have been raised of adverse effects on the heart. While caffeine increases ...

LAST 30 PRESS RELEASES:

Premenstrual symptoms linked to increased risk of cardiovascular disease

Newly discovered remains of ancient river landscapes control ice flow in East Antarctica

Newly discovered interstellar object 'may be oldest comet ever seen'

Animal-inspired AI robot learns to navigate unfamiliar terrain

Underserved youth less likely to visit emergency department for concussion in Ontario, study finds

‘Molecular shield’ placed in the nose may soon treat common hay fever trigger

Beetles under climate stress lay larger male eggs: Wolbachia infection drives adaptive reproduction strategy in response to rising temperature and CO₂

Groundbreaking quantum study puts wave-particle duality to work

Weekly injection could be life changing for Parkinson’s patients

Toxic metals linked to impaired growth in infants in Guatemala

Being consistently physically active in adulthood linked to 30–40% lower risk of death

Nerve pain drug gabapentin linked to increased dementia, cognitive impairment risks

Children’s social care involvement common to nearly third of UK mums who died during perinatal period

‘Support, not judgement’: Study explores links between children’s social care involvement and maternal deaths

Ethnic minority and poorer children more likely to die in intensive care

Major progress in fertility preservation after treatment for cancer of the lymphatic system

Fewer complications after additional ultrasound in pregnant women who feel less fetal movement

Environmental impact of common pesticides seriously underestimated

The Milky Way could be teeming with more satellite galaxies than previously thought

New study reveals surprising reproductive secrets of a cricket-hunting parasitoid fly

Media Tip Sheet: Symposia at ESA2025

NSF CAREER Award will power UVA engineer’s research to improve drug purification

Tiny parasitoid flies show how early-life competition shapes adult success

New coating for glass promises energy-saving windows

Green spaces boost children’s cognitive skills and strengthen family well-being

Ancient trees dying faster than expected in Eastern Oregon

Study findings help hone precision of proven CVD risk tool

Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later

Introducing BioEmu: A generative AI Model that enables high-speed and accurate prediction of protein structural ensembles

Replacing mutated microglia with healthy microglia halts progression of genetic neurological disease in mice and humans

[Press-News.org] The PROTECT study
Low and comparable rates of stent thrombosis found with zotarolimus- and sirolimus-eluting stents: The PROTECT study